VRTX peer analysis
Vertex (VRTX) against its competitors: price, today's move, 1-year return and market value side by side.
VRTX and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALNY Alnylam | $164.99 | -0.01% | -63.30% | $23.31B |
| BBIO BridgeBio Pharma | $75.04 | 0.12% | 18.42% | $13.83B |
| BEAM Beam Therapeutics | $27.40 | 0.62% | 15.13% | $2.98B |
| BMRN BioMarin | $58.51 | 1.77% | 12.71% | $11.13B |
| CRSP CRISPR Therapeutics | $51.95 | 1.03% | -14.98% | $5.25B |
| IONS Ionis Pharmaceuticals | $43.76 | 0.55% | -41.00% | $7.38B |
| NTLA Intellia | $12.60 | 1.04% | 2.73% | $1.85B |
| PTCT PTC Therapeutics | $59.97 | -6.97% | -11.95% | $5.38B |
| RARE Ultragenyx | $16.12 | 0.12% | -53.94% | $1.65B |
| SRPT Sarepta Therapeutics | $18.60 | -0.11% | -20.00% | $2.03B |
| VRTX Vertex | $558.88 | 3.50% | 33.10% | $136.87B |
- VRTX's peers: ALNY (Alnylam), BBIO (BridgeBio Pharma), BEAM (Beam Therapeutics), BMRN (BioMarin), CRSP (CRISPR Therapeutics), IONS (Ionis Pharmaceuticals), NTLA (Intellia), PTCT (PTC Therapeutics).
Updated 2026-11-02 18:28 UTC